Clinical Trials Logo
  1. Home
  2. Adrenal Hyperplasia, Congenital
  3. NCT03162172

Growth Hormone (GH) in Congenital Adrenal Hyperplasia — OPALE GH  

Adrenal Hyperplasia, Congenital Clinical Trial

Official title:
Evaluation of the Adult Height Gain With Growth Hormone Treatment in Children With Congenital Adrenal Hyperplasia (CDAH), Using the OPALE Prediction Model

Clinical Trial Summary

Congenital adrenal hyperplasia (CAH) is a genetic rare disease, which alters the adrenal production of gluco and mineralo corticoids. The treatment consists in supplementing children using hydrocortisone. Despite care for these children has improve substantially across decades, short adult height still remains an important consequence of the disease. About 20 % of patients have an AH below 2 standard deviations compared to their expected height.

In the OPALE model study, the investigators have collected data from a cohort of 496 French patients, born between 1970 and 1991 and with a known genotype. Using their age, sex, growth, disease, bone maturation and pubertal data, they have built a model which allows to predict their AH using data available at 8 years of age. This model has shown that the currently used formula to calculate the predicted AH (Bayley Pineau's method) is not applicable to children with CAH.

In this project, the investigators plan to use the prediction model to compare the AH in patients who have received GH treatment to their predicted AH using the model.

The hypothesis is that GH improves the AH in such patients. Existing cohorts have shown improved growth celerity, and growth expectation using the Bayley-Pineau formula), but this has not been shown on the actual AH.

This study will allow to reinforce the investigators' hypothesis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03162172
Study type Observational
Source Hospices Civils de Lyon
Contact
Status Completed
Phase N/A
Start date September 15, 2015
Completion date March 15, 2016
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT00617292 - Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers N/A
Completed NCT00529841 - Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia N/A
Recruiting NCT05228652 - Questionnaire Study to Assess the Outcomes of the Management of Congenital Adrenal Hyperplasia Individuals
Recruiting NCT01771328 - Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia Phase 2
Active, not recruiting NCT01862380 - Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency. N/A
Completed NCT03589144 - LC-MS / MS Adrenal Steroids Assayed on Dried Blot Spot for the Congenital Adrenal Hyperplasia Neonatal Screening (SPECTROSPOT)
Completed NCT01488721 - Clinical Evaluation of NeoPlex4 Assay and NeoPlex System N/A
Recruiting NCT00694525 - Role of the Protein Osteoprotegerin in the Bone Health of Women With Congenital Adrenal Hyperplasia N/A
Completed NCT00621985 - Dexamethasone Treatment of Congenital Adrenal Hyperplasia Phase 2